Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Meta-Analysis

Association between Statins Types with Incidence of Liver Cancer: An Updated Meta-analysis

Author(s): Xingfen Zhang, Dandi Lou, Rongrong Fu, Feng Wu, Dingcheng Zheng and Xueqiang Ma*

Volume 31, Issue 6, 2024

Published on: 17 July, 2023

Page: [762 - 775] Pages: 14

DOI: 10.2174/0929867330666230701000400

open access plus

Abstract

Background: Previous studies have found a potential role for statins in liver cancer prevention.

Objective: This study aimed to explore the effect of different types of statins on the incidence of liver cancer.

Methods: Relevant articles were systematically retrieved from PubMed, EBSCO, Web of Science, and Cochrane Library databases from inception until July 2022 to explore the relationship between lipophilic statins or hydrophilic statins exposure and the incidence of liver cancer. The main outcome was the incidence of liver cancer.

Results: Eleven articles were included in this meta-analysis. The pooled results showed a reduced incidence of liver cancer in patients exposed to lipophilic statins (OR=0.54, p < 0.001) and hydrophilic statins (OR=0.56, p < 0.001) compared with the non-exposed cohort. Subgroup analysis showed that both exposures to lipophilic (Eastern countries: OR=0.51, p < 0.001; Western countries: OR=0.59, p < 0.001) and hydrophilic (Eastern countries: OR=0.51, p < 0.001; Western countries: OR=0.66, p=0.019) statins reduced the incidence of liver cancer in Eastern and Western countries, and the reduction was most significant in Eastern countries. Moreover, atorvastatin (OR=0.55, p < 0.001), simvastatin (OR=0.59, p < 0.001), lovastatin (OR=0.51, p < 0.001), pitavastatin (OR=0.36, p=0.008) and rosuvastatin (OR=0.60, p=0.027) could effectively reduce the incidence of liver cancer, unlike fluvastatin, cerivastatin and pravastatin.

Conclusion: Both lipophilic and hydrophilic statins contribute to the prevention of liver cancer. Moreover, the efficacy was influenced by the region and the specific type of statins used.

Keywords: Liver cancer, statin, lipophilic statins, hydrophilic statins, incidence, meta-analysis.

[1]
Llovet, J.M.; Kelley, R.K.; Villanueva, A.; Singal, A.G.; Pikarsky, E.; Roayaie, S.; Lencioni, R.; Koike, K.; Zucman-Rossi, J.; Finn, R.S. Hepatocellular carcinoma. Nat. Rev. Dis. Primers, 2021, 7(1), 6.
[http://dx.doi.org/10.1038/s41572-020-00240-3] [PMID: 33479224]
[2]
Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2021, 71(3), 209-249.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[3]
Benson, A.B.; D’Angelica, M.I.; Abbott, D.E.; Anaya, D.A.; Anders, R.; Are, C.; Bachini, M.; Borad, M.; Brown, D.; Burgoyne, A.; Chahal, P.; Chang, D.T.; Cloyd, J.; Covey, A.M.; Glazer, E.S.; Goyal, L.; Hawkins, W.G.; Iyer, R.; Jacob, R.; Kelley, R.K.; Kim, R.; Levine, M.; Palta, M.; Park, J.O.; Raman, S.; Reddy, S.; Sahai, V.; Schefter, T.; Singh, G.; Stein, S.; Vauthey, J.N.; Venook, A.P.; Yopp, A.; McMillian, N.R.; Hochstetler, C.; Darlow, S.D. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw., 2021, 19(5), 541-565.
[http://dx.doi.org/10.6004/jnccn.2021.0022] [PMID: 34030131]
[4]
Allemani, C.; Matsuda, T.; Di Carlo, V.; Harewood, R.; Matz, M.; Nikšić, M.; Bonaventure, A.; Valkov, M.; Johnson, C.J.; Estève, J.; Ogunbiyi, O.J.; Azevedo e Silva, G.; Chen, W.Q.; Eser, S.; Engholm, G.; Stiller, C.A.; Monnereau, A.; Woods, R.R.; Visser, O.; Lim, G.H.; Aitken, J.; Weir, H.K.; Coleman, M.P.; Bouzbid, S.; Hamdi-Chérif, M.; Zaidi, Z.; Meguenni, K.; Regagba, D.; Bayo, S.; Cheick Bougadari, T.; Manraj, S.S.; Bendahhou, K.; Fabowale, A.; Bradshaw, D.; Somdyala, N.I.M.; Kumcher, I.; Moreno, F.; Calabrano, G.H.; Espinola, S.B.; Carballo Quintero, B.; Fita, R.; Diumenjo, M.C.; Laspada, W.D.; Ibañez, S.G.; Lima, C.A.; De Souza, P.C.F.; Del Pino, K.; Laporte, C.; Curado, M.P.; de Oliveira, J.C.; Veneziano, C.L.A.; Veneziano, D.B.; Latorre, M.R.D.O.; Tanaka, L.F.; Rebelo, M.S.; Santos, M.O.; Galaz, J.C.; Aparicio Aravena, M.; Sanhueza Monsalve, J.; Herrmann, D.A.; Vargas, S.; Herrera, V.M.; Uribe, C.J.; Bravo, L.E.; Garcia, L.S.; Arias-Ortiz, N.E.; Morantes, D.; Jurado, D.M.; Yépez Chamorro, M.C.; Delgado, S.; Ramirez, M.; Galán Alvarez, Y.H.; Torres, P.; Martínez-Reyes, F.; Jaramillo, L.; Quinto, R.; Castillo, J.; Mendoza, M.; Cueva, P.; Yépez, J.G.; Bhakkan, B.; Deloumeaux, J.; Joachim, C.; Macni, J.; Carrillo, R.; Shalkow Klincovstein, J.; Rivera Gomez, R.; Poquioma, E.; Tortolero-Luna, G.; Zavala, D.; Alonso, R.; Barrios, E.; Eckstrand, A.; Nikiforuk, C.; Noonan, G.; Turner, D.; Kumar, E.; Zhang, B.; McCrate, F.R.; Ryan, S.; MacIntyre, M.; Saint-Jacques, N.; Nishri, D.E.; McClure, C.A.; Vriends, K.A.; Kozie, S.; Stuart-Panko, H.; Freeman, T.; George, J.T.; Brockhouse, J.T.; O’Brien, D.K.; Holt, A.; Almon, L.; Kwong, S.; Morris, C.; Rycroft, R.; Mueller, L.; Phillips, C.E.; Brown, H.; Cromartie, B.; Schwartz, A.G.; Vigneau, F.; Levin, G.M.; Wohler, B.; Bayakly, R.; Ward, K.C.; Gomez, S.L.; McKinley, M.; Cress, R.; Green, M.D.; Miyagi, K.; Ruppert, L.P.; Lynch, C.F.; Huang, B.; Tucker, T.C.; Deapen, D.; Liu, L.; Hsieh, M.C.; Wu, X.C.; Schwenn, M.; Gershman, S.T.; Knowlton, R.C.; Alverson, G.; Copeland, G.E.; Bushhouse, S.; Rogers, D.B.; Jackson-Thompson, J.; Lemons, D.; Zimmerman, H.J.; Hood, M.; Roberts-Johnson, J.; Rees, J.R.; Riddle, B.; Pawlish, K.S.; Stroup, A.; Key, C.; Wiggins, C.; Kahn, A.R.; Schymura, M.J.; Radhakrishnan, S.; Rao, C.; Giljahn, L.K.; Slocumb, R.M.; Espinoza, R.E.; Khan, F.; Aird, K.G.; Beran, T.; Rubertone, J.J.; Slack, S.J.; Garcia, L.; Rousseau, D.L.; Janes, T.A.; Schwartz, S.M.; Bolick, S.W.; Hurley, D.M.; Whiteside, M.A.; Miller-Gianturco, P.; Williams, M.A.; Herget, K.; Sweeney, C.; Johnson, A.T.; Keitheri Cheteri, M.B.; Migliore Santiago, P.; Blankenship, S.E.; Farley, S.; Borchers, R.; Malicki, R.; Espinoza, J.R.; Grandpre, J.; Wilson, R.; Edwards, B.K.; Mariotto, A.; Lei, Y.; Wang, N.; Chen, J.S.; Zhou, Y.; He, Y.T.; Song, G.H.; Gu, X.P.; Mei, D.; Mu, H.J.; Ge, H.M.; Wu, T.H.; Li, Y.Y.; Zhao, D.L.; Jin, F.; Zhang, J.H.; Zhu, F.D.; Junhua, Q.; Yang, Y.L.; Jiang, C.X.; Biao, W.; Wang, J.; Li, Q.L.; Yi, H.; Zhou, X.; Dong, J.; Li, W.; Fu, F.X.; Liu, S.Z.; Chen, J.G.; Zhu, J.; Li, Y.H.; Lu, Y.Q.; Fan, M.; Huang, S.Q.; Guo, G.P.; Zhaolai, H.; Wei, K.; Zeng, H.; Demetriou, A.V.; Mang, W.K.; Ngan, K.C.; Kataki, A.C.; Krishnatreya, M.; Jayalekshmi, P.A.; Sebastian, P.; Nandakumar, A.; Malekzadeh, R.; Roshandel, G.; Keinan-Boker, L.; Silverman, B.G.; Ito, H.; Nakagawa, H.; Sato, M.; Tobori, F.; Nakata, I.; Teramoto, N.; Hattori, M.; Kaizaki, Y.; Moki, F.; Sugiyama, H.; Utada, M.; Nishimura, M.; Yoshida, K.; Kurosawa, K.; Nemoto, Y.; Narimatsu, H.; Sakaguchi, M.; Kanemura, S.; Naito, M.; Narisawa, R.; Miyashiro, I.; Nakata, K.; Sato, S.; Yoshii, M.; Oki, I.; Fukushima, N.; Shibata, A.; Iwasa, K.; Ono, C.; Nimri, O.; Jung, K.W.; Won, Y.J.; Alawadhi, E.; Elbasmi, A.; Ab Manan, A.; Adam, F.; Sanjaajmats, E.; Tudev, U.; Ochir, C.; Al Khater, A.M.; El Mistiri, M.M.; Teo, Y.Y.; Chiang, C.J.; Lee, W.C.; Buasom, R.; Sangrajrang, S.; Kamsa-ard, S.; Wiangnon, S.; Daoprasert, K.; Pongnikorn, D.; Leklob, A.; Sangkitipaiboon, S.; Geater, S.L.; Sriplung, H.; Ceylan, O.; Kög, I.; Dirican, O.; Köse, T.; Gurbuz, T.; Karaşahin, F.E.; Turhan, D.; Aktaş, U.; Halat, Y.; Yakut, C.I.; Altinisik, M.; Cavusoglu, Y.; Türkköylü, A.; Üçüncü, N.; Hackl, M.; Zborovskaya, A.A.; Aleinikova, O.V.; Henau, K.; Van Eycken, L.; Valerianova, Z.; Yordanova, M.R.; Šekerija, M.; Dušek, L.; Zvolský, M.; Storm, H.; Innos, K.; Mägi, M.; Malila, N.; Seppä, K.; Jégu, J.; Velten, M.; Cornet, E.; Troussard, X.; Bouvier, A.M.; Guizard, A.V.; Bouvier, V.; Launoy, G.; Arveux, P.; Maynadié, M.; Mounier, M.; Woronoff, A.S.; Daoulas, M.; Robaszkiewicz, M.; Clavel, J.; Goujon, S.; Lacour, B.; Baldi, I.; Pouchieu, C.; Amadeo, B.; Coureau, G.; Orazio, S.; Preux, P.M.; Rharbaoui, F.; Marrer, E.; Trétarre, B.; Colonna, M.; Delafosse, P.; Ligier, K.; Plouvier, S.; Cowppli-Bony, A.; Molinié, F.; Bara, S.; Ganry, O.; Lapôtre-Ledoux, B.; Grosclaude, P.; Bossard, N.; Uhry, Z.; Bray, F.; Piñeros, M.; Stabenow, R.; Wilsdorf-Köhler, H.; Eberle, A.; Luttmann, S.; Löhden, I.; Nennecke, A.L.; Kieschke, J.; Sirri, E.; Emrich, K.; Zeissig, S.R.; Holleczek, B.; Eisemann, N.; Katalinic, A.; Asquez, R.A.; Kumar, V.; Petridou, E.; Ólafsdóttir, E.J.; Tryggvadóttir, L.; Clough-Gorr, K.; Walsh, P.M.; Sundseth, H.; Mazzoleni, G.; Vittadello, F.; Coviello, E.; Cuccaro, F.; Galasso, R.; Sampietro, G.; Giacomin, A.; Magoni, M.; Ardizzone, A.; D’Argenzio, A.; Castaing, M.; Grosso, G.; Lavecchia, A.M.; Sutera Sardo, A.; Gola, G.; Gatti, L.; Ricci, P.; Ferretti, S.; Serraino, D.; Zucchetto, A.; Celesia, M.V.; Filiberti, R.A.; Pannozzo, F.; Melcarne, A.; Quarta, F.; Russo, A.G.; Carrozzi, G.; Cirilli, C.; Cavalieri d’Oro, L.; Rognoni, M.; Fusco, M.; Vitale, M.F.; Usala, M.; Cusimano, R.; Mazzucco, W.; Michiara, M.; Sgargi, P.; Boschetti, L.; Borciani, E.; Seghini, P.; Maule, M.M.; Merletti, F.; Tumino, R.; Mancuso, P.; Vicentini, M.; Cassetti, T.; Sassatelli, R.; Falcini, F.; Giorgetti, S.; Caiazzo, A.L.; Cavallo, R.; Cesaraccio, R.; Pirino, D.R.; Contrino, M.L.; Tisano, F.; Fanetti, A.C.; Maspero, S.; Carone, S.; Mincuzzi, A.; Candela, G.; Scuderi, T.; Gentilini, M.A.; Piffer, S.; Rosso, S.; Barchielli, A.; Caldarella, A.; Bianconi, F.; Stracci, F.; Contiero, P.; Tagliabue, G.; Rugge, M.; Zorzi, M.; Beggiato, S.; Brustolin, A.; Berrino, F.; Gatta, G.; Sant, M.; Buzzoni, C.; Mangone, L.; Capocaccia, R.; De Angelis, R.; Zanetti, R.; Maurina, A.; Pildava, S.; Lipunova, N.; Vincerževskiené, I.; Agius, D.; Calleja, N.; Siesling, S.; Larønningen, S.; Møller, B.; Dyzmann-Sroka, A.; Trojanowski, M.; Góźdź, S.; Mężyk, R.; Mierzwa, T.; Molong, L.; Rachtan, J.; Szewczyk, S.; Błaszczyk, J.; Kępska, K.; Kościańska, B.; Tarocińska, K.; Zwierko, M.; Drosik, K.; Maksimowicz, K.M.; Purwin-Porowska, E.; Reca, E.; Wójcik-Tomaszewska, J.; Tukiendorf, A.; Grądalska-Lampart, M.; Radziszewska, A.U.; Gos, A.; Talerczyk, M.; Wyborska, M.; Didkowska, J.A.; Wojciechowska, U.; Bielska-Lasota, M.; Forjaz de Lacerda, G.; Rego, R.A.; Bastos, J.; Silva, M.A.; Antunes, L.; Laranja Pontes, J.; Mayer-da-Silva, A.; Miranda, A.; Blaga, L.M.; Coza, D.; Gusenkova, L.; Lazarevich, O.; Prudnikova, O.; Vjushkov, D.M.; Egorova, A.G.; Orlov, A.E.; Kudyakov, L.A.; Pikalova, L.V.; Adamcik, J.; Safaei Diba, C.; Primic-Žakelj, M.; Zadnik, V.; Larrañaga, N.; Lopez de Munain, A.; Herrera, A.A.; Redondas, R.; Marcos-Gragera, R.; Vilardell Gil, M.L.; Molina, E.; Sánchez Perez, M.J.; Franch Sureda, P.; Ramos Montserrat, M.; Chirlaque, M.D.; Navarro, C.; Ardanaz, E.E.; Guevara, M.M.; Fernández-Delgado, R.; Peris-Bonet, R.; Carulla, M.; Galceran, J.; Alberich, C.; Vicente-Raneda, M.; Khan, S.; Pettersson, D.; Dickman, P.; Avelina, I.; Staehelin, K.; Camey, B.; Bouchardy, C.; Schaffar, R.; Frick, H.; Herrmann, C.; Bulliard, J.L.; Maspoli-Conconi, M.; Kuehni, C.E.; Redmond, S.M.; Bordoni, A.; Ortelli, L.; Chiolero, A.; Konzelmann, I.; Matthes, K.L.; Rohrmann, S.; Broggio, J.; Rashbass, J.; Fitzpatrick, D.; Gavin, A.; Clark, D.I.; Deas, A.J.; Huws, D.W.; White, C.; Montel, L.; Rachet, B.; Turculet, A.D.; Stephens, R.; Chalker, E.; Phung, H.; Walton, R.; You, H.; Guthridge, S.; Johnson, F.; Gordon, P.; D’Onise, K.; Priest, K.; Stokes, B.C.; Venn, A.; Farrugia, H.; Thursfield, V.; Dowling, J.; Currow, D.; Hendrix, J.; Lewis, C. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018, 391(10125), 1023-1075.
[http://dx.doi.org/10.1016/S0140-6736(17)33326-3] [PMID: 29395269]
[5]
Kazi, D.S.; Penko, J.M.; Bibbins-Domingo, K. Statins for primary prevention of cardiovascular disease. Med. Clin. North Am., 2017, 101(4), 689-699.
[http://dx.doi.org/10.1016/j.mcna.2017.03.001] [PMID: 28577620]
[6]
Jiang, W.; Hu, J.W.; He, X.R.; Jin, W.L.; He, X.Y. Statins: A repurposed drug to fight cancer. J. Exp. Clin. Cancer Res., 2021, 40(1), 241.
[http://dx.doi.org/10.1186/s13046-021-02041-2] [PMID: 34303383]
[7]
Lou, D.; Fu, R.; Gu, L.; Su, H.; Guan Association between statins’ exposure with incidence and prognosis of gastric cancer: an updated meta-analysis. Expert Rev. Clin. Pharmacol., 2022, 15(9), 1127-1138.
[http://dx.doi.org/10.1080/17512433.2022.2112178] [PMID: 35947078]
[8]
Rodríguez-Miguel, A.; Fernández-Antón, E.; Barreira-Hernández, D.; García-Rodríguez, L.A.; Gil, M.; García-Lledó, A.; De Abajo, F.J. Statins and colorectal cancer risk: A population-based case-control study and synthesis of the epidemiological evidence. J. Clin. Med., 2022, 11(6), 1528.
[http://dx.doi.org/10.3390/jcm11061528] [PMID: 35329853]
[9]
Islam, M.M.; Yang, H.C.; Nguyen, P.A.; Poly, T.N.; Huang, C.W.; Kekade, S.; Khalfan, A.M.; Debnath, T.; Li, Y.C.J.; Abdul, S.S. Exploring association between statin use and breast cancer risk: An updated meta-analysis. Arch. Gynecol. Obstet., 2017, 296(6), 1043-1053.
[http://dx.doi.org/10.1007/s00404-017-4533-3] [PMID: 28940025]
[10]
Yang, L.; Wei, Q.; Tan, P.; Zhang, C.; Wei, S-Y.; Tang, Z.; Gao, L. Effect of statins type on incident prostate cancer risk: A meta-analysis and systematic review. Asian J. Androl., 2017, 19(6), 666-671.
[http://dx.doi.org/10.4103/1008-682X.190327] [PMID: 27924788]
[11]
Wang, Y.; Wang, W.; Wang, M.; Shi, J.; Jia, X.; Dang, S. A meta-analysis of statin use and risk of hepatocellular carcinoma. Can. J. Gastroenterol. Hepatol., 2022, 2022, 1-15.
[http://dx.doi.org/10.1155/2022/5389044] [PMID: 35356132]
[12]
Facciorusso, A.; Abd El Aziz, M.A.; Singh, S.; Pusceddu, S.; Milione, M.; Giacomelli, L.; Sacco, R. Statin use decreases the incidence of hepatocellular carcinoma: An updated meta-analysis. Cancers, 2020, 12(4), 874.
[http://dx.doi.org/10.3390/cancers12040874] [PMID: 32260179]
[13]
Climent, E.; Benaiges, D.; Pedro-Botet, J. Hydrophilic or lipophilic statins? Front. Cardiovasc. Med., 2021, 8, 687585.
[http://dx.doi.org/10.3389/fcvm.2021.687585] [PMID: 34095267]
[14]
Murphy, C.; Deplazes, E.; Cranfield, C.G.; Garcia, A. The role of structure and biophysical properties in the pleiotropic effects of statins. Int. J. Mol. Sci., 2020, 21(22), 8745.
[http://dx.doi.org/10.3390/ijms21228745] [PMID: 33228116]
[15]
Liu, Y.; Tang, W.; Wang, J.; Xie, L.; Li, T.; He, Y.; Deng, Y.; Peng, Q.; Li, S.; Qin, X. Association between statin use and colorectal cancer risk: A meta-analysis of 42 studies. Cancer Causes Control, 2014, 25(2), 237-249.
[http://dx.doi.org/10.1007/s10552-013-0326-6] [PMID: 24265089]
[16]
Babcook, M.A.; Joshi, A.; Montellano, J.A.; Shankar, E.; Gupta, S. Statin use in prostate cancer: An update. Nutr. Metab. Insights, 2016, 9, NMI.S38362.
[http://dx.doi.org/10.4137/NMI.S38362] [PMID: 27441003]
[17]
Shi, M.; Zheng, H.; Nie, B.; Gong, W.; Cui, X. Statin use and risk of liver cancer: An update meta-analysis. BMJ Open, 2014, 4(9), e005399.
[http://dx.doi.org/10.1136/bmjopen-2014-005399] [PMID: 25227628]
[18]
Chang, Y.; Liu, Q.; Zhou, Z.; Ding, Y.; Yang, M.; Xu, W.; Chen, K.; Zhang, Q.; Wang, Z.; Li, H. Can statin treatment reduce the risk of hepatocellular carcinoma? a systematic review and meta-analysis. Technol. Cancer Res. Treat., 2020, 19
[http://dx.doi.org/10.1177/1533033820934881] [PMID: 32552476]
[19]
Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; Chou, R.; Glanville, J.; Grimshaw, J.M.; Hróbjartsson, A.; Lalu, M.M.; Li, T.; Loder, E.W.; Mayo-Wilson, E.; McDonald, S.; McGuinness, L.A.; Stewart, L.A.; Thomas, J.; Tricco, A.C.; Welch, V.A.; Whiting, P.; Moher, D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 2021, 372(71), n71.
[http://dx.doi.org/10.1136/bmj.n71] [PMID: 33782057]
[20]
El-Serag, H.B.; Johnson, M.L.; Hachem, C.; Morgana, R.O. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology, 2009, 136(5), 1601-1608.
[http://dx.doi.org/10.1053/j.gastro.2009.01.053] [PMID: 19208359]
[21]
Kim, G.; Jang, S.Y.; Han, E.; Lee, Y.; Park, S.; Nam, C.M.; Kang, E.S. Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study. Int. J. Cancer, 2017, 140(4), 798-806.
[http://dx.doi.org/10.1002/ijc.30506] [PMID: 27861855]
[22]
Kim, G.; Jang, S.Y.; Nam, C.M.; Kang, E.S. Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study. J. Hepatol., 2018, 68(3), 476-484.
[http://dx.doi.org/10.1016/j.jhep.2017.10.018] [PMID: 29107150]
[23]
Kim, H.W.; Joo, Y.S.; Kang, S.C.; Koh, H.B.; Han, S.H.; Yoo, T.H.; Kang, S.W.; Park, J.T. Association of statin treatment with hepatocellular carcinoma risk in end-stage kidney disease patients with chronic viral hepatitis. Sci. Rep., 2022, 12(1), 10807.
[http://dx.doi.org/10.1038/s41598-022-14713-w] [PMID: 35752695]
[24]
Lai, S.W.; Liao, K.F.; Lai, H.C.; Muo, C.H.; Sung, F.C.; Chen, P.C. Statin use and risk of hepatocellular carcinoma. Eur. J. Epidemiol., 2013, 28(6), 485-492.
[http://dx.doi.org/10.1007/s10654-013-9806-y] [PMID: 23681775]
[25]
McGlynn, K.A.; Hagberg, K.; Chen, J.; Graubard, B.I.; London, W.T.; Jick, S.; Sahasrabuddhe, V.V. Statin use and risk of primary liver cancer in the clinical practice research datalink. J. Natl. Cancer Inst., 2015, 107(4), djv009.
[http://dx.doi.org/10.1093/jnci/djv009] [PMID: 25722350]
[26]
Pinyopornpanish, K.; Al-Yaman, W.; Butler, R.S.; Carey, W.; McCullough, A.; Romero-Marrero, C. Chemopreventive effect of statin on hepatocellular carcinoma in patients with nonalcoholic steatohepatitis cirrhosis. Am. J. Gastroenterol., 2021, 116(11), 2258-2269.
[http://dx.doi.org/10.14309/ajg.0000000000001347] [PMID: 34212895]
[27]
Sung, F.C.; Yeh, Y.T.; Muo, C.H.; Hsu, C.C.; Tsai, W.C.; Hsu, Y.H. Statins reduce hepatocellular carcinoma risk in patients with chronic kidney disease and end-stage renal disease: A 17-year longitudinal study. Cancers, 2022, 14(3), 825.
[http://dx.doi.org/10.3390/cancers14030825] [PMID: 35159093]
[28]
Tran, K.T.; McMenamin, Ú.C.; Coleman, H.G.; Cardwell, C.R.; Murchie, P.; Iversen, L.; Lee, A.J.; Thrift, A.P. Statin use and risk of liver cancer: Evidence from two population-based studies. Int. J. Cancer, 2020, 146(5), 1250-1260.
[http://dx.doi.org/10.1002/ijc.32426] [PMID: 31112291]
[29]
Tsan, Y.T.; Lee, C.H.; Wang, J.D.; Chen, P.C. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J. Clin. Oncol., 2012, 30(6), 623-630.
[http://dx.doi.org/10.1200/JCO.2011.36.0917] [PMID: 22271485]
[30]
Zou, B.; Odden, M.C.; Nguyen, M.H. Statin use and reduced hepatocellular carcinoma risk in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol., 2022.
[PMID: 35158055]
[31]
Sutter, A.P.; Maaser, K.; Höpfner, M.; Huether, A.; Schuppan, D.; Scherübl, H. Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. J. Hepatol., 2005, 43(5), 808-816.
[http://dx.doi.org/10.1016/j.jhep.2005.04.010] [PMID: 16083991]
[32]
Relja, B.; Meder, F.; Wilhelm, K.; Henrich, D.; Marzi, I.; Lehnert, M. Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int. J. Mol. Med., 2010, 26(5), 735-741.
[http://dx.doi.org/10.3892/ijmm_00000520] [PMID: 20878096]
[33]
Cao, Z.; Fan-Minogue, H.; Bellovin, D.I.; Yevtodiyenko, A.; Arzeno, J.; Yang, Q.; Gambhir, S.S.; Felsher, D.W. MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Res., 2011, 71(6), 2286-2297.
[http://dx.doi.org/10.1158/0008-5472.CAN-10-3367] [PMID: 21262914]
[34]
Shachaf, C.M.; Kopelman, A.M.; Arvanitis, C.; Karlsson, Å.; Beer, S.; Mandl, S.; Bachmann, M.H.; Borowsky, A.D.; Ruebner, B.; Cardiff, R.D.; Yang, Q.; Bishop, J.M.; Contag, C.H.; Felsher, D.W. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature, 2004, 431(7012), 1112-1117.
[http://dx.doi.org/10.1038/nature03043] [PMID: 15475948]
[35]
Kopecka, J.; Trouillas, P.; Gašparović, A.Č.; Gazzano, E.; Assaraf, Y.G.; Riganti, C. Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets. Drug Resist. Updat., 2020, 49, 100670.
[http://dx.doi.org/10.1016/j.drup.2019.100670] [PMID: 31846838]
[36]
Jiang, P.; Mukthavaram, R.; Chao, Y.; Nomura, N.; Bharati, I. S.; Fogal, V.; Pastorino, S.; Teng, D.; Cong, X.; Pingle, S. C.; Kapoor, S.; Shetty, K.; Aggrawal, A.; Vali, S.; Abbasi, T.; Chien, S.; Kesari, S. In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells. Br J Cancer, 2014, 111(8), 1562-1571.
[http://dx.doi.org/10.1038/bjc.2014.431]
[37]
Jang, H.J.; Hong, E.M.; Kim, M.; Kim, J.H.; Jang, J.; Park, S.W.; Byun, H.W.; Koh, D.H.; Choi, M.H.; Kae, S.H.; Lee, J. Simvastatin induces heme oxygenase-1 via NF-E2-related factor 2 (Nrf2) activation through ERK and PI3K/Akt pathway in colon cancer. Oncotarget, 2016, 7(29), 46219-46229.
[38]
Wei, T.T.; Lin, Y.T.; Chen, W.S.; Luo, P.; Lin, Y.C.; Shun, C.T.; Lin, Y.H.; Chen, J.B.; Chen, N.W.; Fang, J.M.; Wu, M.S.; Yang, K.C.; Chang, L.C.; Tai, K.Y.; Liang, J.T.; Chen, C.C. Dual targeting of 3-hydroxy-3-methylglutaryl coenzyme a reductase and histone deacetylase as a therapy for colorectal cancer. EBioMedicine, 2016, 10, 124-136.
[http://dx.doi.org/10.1016/j.ebiom.2016.07.019] [PMID: 27448759]
[39]
Schachter, M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundam. Clin. Pharmacol., 2005, 19(1), 117-125.
[http://dx.doi.org/10.1111/j.1472-8206.2004.00299.x] [PMID: 15660968]
[40]
Egom, E.E.A.; Hafeez, H. Biochemistry of statins. Adv. Clin. Chem., 2016, 73, 127-168.
[http://dx.doi.org/10.1016/bs.acc.2015.10.005] [PMID: 26975972]
[41]
Ye, J.; Wang, C.; Sumpter, R., Jr; Brown, M.S.; Goldstein, J.L.; Gale, M., Jr Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc. Natl. Acad. Sci., 2003, 100(26), 15865-15870.
[http://dx.doi.org/10.1073/pnas.2237238100] [PMID: 14668447]
[42]
Zhao, T.T.; Le Francois, B.G.; Goss, G.; Ding, K.; Bradbury, P.A.; Dimitroulakos, J. Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: Potential regulation by targeting rho proteins. Oncogene, 2010, 29(33), 4682-4692.
[http://dx.doi.org/10.1038/onc.2010.219] [PMID: 20562912]
[43]
Lupberger, J.; Zeisel, M.B.; Xiao, F.; Thumann, C.; Fofana, I.; Zona, L.; Davis, C.; Mee, C.J.; Turek, M.; Gorke, S.; Royer, C.; Fischer, B.; Zahid, M.N.; Lavillette, D.; Fresquet, J.; Cosset, F.L.; Rothenberg, S.M.; Pietschmann, T.; Patel, A.H.; Pessaux, P.; Doffoël, M.; Raffelsberger, W.; Poch, O.; McKeating, J.A.; Brino, L.; Baumert, T.F. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat. Med., 2011, 17(5), 589-595.
[http://dx.doi.org/10.1038/nm.2341] [PMID: 21516087]
[44]
Li, X.; Sheng, L.; Liu, L.; Hu, Y.; Chen, Y.; Lou, L. Statin and the risk of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: A meta-analysis. BMC Gastroenterol., 2020, 20(1), 98.
[http://dx.doi.org/10.1186/s12876-020-01222-1] [PMID: 32272891]
[45]
Goh, M.J.; Sinn, D.H.; Kim, S.; Woo, S.Y.; Cho, H.; Kang, W.; Gwak, G.Y.; Paik, Y.H.; Choi, M.S.; Lee, J.H.; Koh, K.C.; Paik, S.W. Statin use and the risk of hepatocellular carcinoma in patients with chronic hepatitis B. Hepatology, 2020, 71(6), 2023-2032.
[http://dx.doi.org/10.1002/hep.30973] [PMID: 31556128]
[46]
Fang, C.; Pan, J.; Qu, N.; Lei, Y.; Han, J.; Zhang, J.; Han, D. The AMPK pathway in fatty liver disease. Front. Physiol., 2022, 13, 970292.
[http://dx.doi.org/10.3389/fphys.2022.970292] [PMID: 36203933]
[47]
Fatima, K.; Moeed, A.; Waqar, E.; Atif, A.R.; Kamran, A.; Rizvi, H.; Suri, N.F.; Haider, H.; Shuja, S.H.; Khalid, M.; Minhas, A.M.K. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis. Clin. Res. Hepatol. Gastroenterol., 2022, 46(4), 101816.
[http://dx.doi.org/10.1016/j.clinre.2021.101816] [PMID: 34607067]
[48]
Boutari, C.; Pappas, P.D.; Anastasilakis, D.; Mantzoros, C.S. Statins’ efficacy in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clin. Nutr., 2022, 41(10), 2195-2206.
[http://dx.doi.org/10.1016/j.clnu.2022.08.001] [PMID: 36081293]
[49]
Lee, S.H.; Choi, N.Y.; Yu, H.J.; Park, J.; Choi, H.; Lee, K.Y.; Huh, Y.M.; Lee, Y.J.; Koh, S.H. Atorvastatin protects NSC-34 motor neurons against oxidative stress by activating PI3K, ERK and free radical scavenging. Mol. Neurobiol., 2016, 53(1), 695-705.
[http://dx.doi.org/10.1007/s12035-014-9030-0] [PMID: 25577170]
[50]
Trebicka, J.; Hennenberg, M.; Odenthal, M.; Shir, K.; Klein, S.; Granzow, M.; Vogt, A.; Dienes, H.P.; Lammert, F.; Reichen, J.; Heller, J.; Sauerbruch, T. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J. Hepatol., 2010, 53(4), 702-712.
[http://dx.doi.org/10.1016/j.jhep.2010.04.025] [PMID: 20633948]
[51]
Kim, M.H.; Kim, M.Y.; Salloum, S.; Qian, T.; Wong, L.P.; Xu, M.; Lee, Y.; Shroff, S.G.; Sadreyev, R.I.; Corey, K.E.; Baumert, T.F.; Hoshida, Y.; Chung, R.T. Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature. Hepatol. Commun., 2022, 6(9), 2581-2593.
[http://dx.doi.org/10.1002/hep4.1991] [PMID: 35712812]
[52]
Yu, Z.; Guo, J.; Liu, Y.; Wang, M.; Liu, Z.; Gao, Y.; Huang, L. Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma. J. Nanobiotechnology, 2022, 20(1), 9.
[http://dx.doi.org/10.1186/s12951-021-01205-8] [PMID: 34983554]
[53]
Liu, S.; Uppal, H.; Demaria, M.; Desprez, P. Y.; Campisi, J.; Kapahi, P. Simvastatin suppresses breast cancer cell proliferation induced by senescent cells. Sci Rep, 2015, 5, 17895.
[http://dx.doi.org/10.1038/srep17895]
[54]
Xie, L.; Zhu, G.; Shang, J.; Chen, X.; Zhang, C.; Ji, X.; Zhang, Q.; Wei, Y. An overview on the biological activity and anti-cancer mechanism of lovastatin. Cell. Signal., 2021, 87, 110122.
[http://dx.doi.org/10.1016/j.cellsig.2021.110122] [PMID: 34438015]
[55]
Deezagi, A.; Safari, N. Rosuvastatin inhibit spheroid formation and epithelial–mesenchymal transition (EMT) in prostate cancer PC-3 cell line. Mol. Biol. Rep., 2020, 47(11), 8727-8737.
[http://dx.doi.org/10.1007/s11033-020-05918-1] [PMID: 33085048]
[56]
Jiao, Z.; Cai, H.; Long, Y.; Sirka, O.K.; Padmanaban, V.; Ewald, A.J.; Devreotes, P.N. Statin-induced GGPP depletion blocks macropinocytosis and starves cells with oncogenic defects. Proc. Natl. Acad. Sci., 2020, 117(8), 4158-4168.
[http://dx.doi.org/10.1073/pnas.1917938117] [PMID: 32051246]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy